07:47 AM EDT, 08/12/2024 (MT Newswires) -- Pfizer ( PFE ) said Monday the topline results of a phase 3 trial for Abrysvo showed a substantial immunity response in patients tested with the vaccine.

The trial evaluates Abrysvo in immunocompromised adults at risk of developing severe lower respiratory tract disease associated with respiratory syncytial virus.

Abrysvo is also found to be well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine, the company said.

Pfizer ( PFE ) also said a single dose of the vaccine triggered a "strong neutralizing response" against the two subtypes of RSV.

Price: 28.60, Change: +0.05, Percent Change: +0.18